viewDyadic International Inc

Dyadic announces new milestone as G2 human-like glycosylation reached

The company's C1 strain has been glyco-engineered to achieve a core human-like G2 glycan level over 76% on Host Cell Proteins

Dyadic International Inc - Dyadic International Inc announces new milestone as G2 human-like glycosylation reached
The data were presented recently at the 15th European Conference on Fungal Genetics in Rome

Dyadic International Inc (NASDAQ:DYAI) announced Monday that data presented at the 15th European Conference on Fungal Genetics demonstrated that its C1 strain has been glyco-engineered to achieve a core human-like G2 glycan level over 76% on Host Cell Proteins (HCP).

According to a statement, the G2 glycosylation data was presented by Anne Huuskonen from the VTT Technical Research Centre of Finland Ltd at the conference in Rome on February 19. The scientific results are outlined in the presentation entitled, ''Development of filamentous fungus Myceliophthora thermophila C1 into a next-generation therapeutic protein production system." 

An overview of the presentation is available on Dyadic's website: www.dyadic.com/wp-content/uploads/2020/02/VTT-AHuuskonen-Rome-2-19-2020.pdf https://pr.report/UvgLTA3y

READ: Dyadic says C1 antigen shows strong performance in protecting animals from devastating virus

"Our collaboration with Dyadic continues to achieve new scientific milestones regarding glycoengineering Dyadic's C1 industrially proven cell line, building upon the 95% core human G0 glycosylation milestone that was reported by Markku Saloheimo, senior principal scientist at VTT, during the PEGS Europe (Protein & Antibody Engineering Summit) in November 2019," said Huuskonen. 

Ronen Tchelet, Dyadic's chief scientific officer, said: "Our C1 glycoengineering efforts continue to target our goals in developing C1 cell lines that produce high proportions of human-like glycoforms such as G0, G2, G0F and G2F on heterologous proteins. 

"In addition to the glycosylation results, VTT also presented data showing that we continue to make excellent progress in reducing the extracellular protease background by fifty (50) times in C1. The elimination of protease activity makes the C1 cell line more efficient, leading to even higher expression levels and lower cost than before."

Matthew Jones, Dyadic's chief commercial officer, said the G0 and G2 glycosylation and other scientific advances further demonstrate the power of the C1 gene expression platform.

“We expect that these scientific achievements will open new doors to apply C1 to a broader array of glycosylated biopharmaceuticals, further extend the company's market opportunities for biologic vaccines and drugs and continue to generate interest from biotech and pharmaceutical companies, academic and other institutes as well as governmental agencies in animal and human health industries."

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Dyadic International Inc

Price: 8.95 USD

Market: NASDAQ
Market Cap: $245.85 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...



Dyadic working with global research partners to express potential...

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb tells Proactive the Florida-based biotech is 'delivering on its promises.' Emalfarb says it saw a busy first quarter where the company stepped up in the global fight against the coronavirus pandemic. Emalfarb says among its recent...

on 05/15/2020

2 min read